CoChat

Mirtazapine: A Review of its Use in Major Depression and Other Psychiatric Disorders

The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.

Abstract

Mirtazapine (Remeron, Zispin) is a noradrenergic and specific serotonergic antidepressant (NaSSA) that is approved in many counties for use in the treatment of major depression. Monotherapy with mirtazapine 15-45 mg/day leads to rapid and sustained improvements in depressive symptoms in patients with major depression, including the elderly. It is as effective as other antidepressants and may have a more rapid onset of action than selective serotonin reuptake inhibitors (SSRIs). Furthermore, it may also have a higher sustained remission rate than amitriptyline. Preliminary data suggest that mirtazapine may also be effective in the treatment of anxiety disorders (including post-traumatic stress disorder, panic disorder and social anxiety disorder), obsessive-compulsive disorder, undifferentiated somatoform disorder and, as add-on therapy, in schizophrenia, although large, well designed trials are needed to confirm these findings. Mirtazapine is generally well tolerated in patients with depression. In conclusion, mirtazapine is an effective antidepressant for the treatment of major depression and also has the potential to be of use in other psychiatric indications.

Overview

Integrity signals

Registry

Crossref · 10.2165/00023210-200923050-00006

Cites

129 of 129 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 129 references

Research works printed but not linked: 13

  1. Bruijn, 1996, Psychopharmacol, 127, 231, 10.1007/BF02246131 · doi:10.1007/bf02246131
  2. Kinoshita, 2009, Jpn J Clin Psychopharmacol, 12, 289
  3. Kinoshita, 2009, Jpn J Clin Psychopharmacol, 12, 503
  4. Bremner, 1995, J Clin Psychiatry, 56, 519
  5. Smith, 1990, Psychopharmacol Bull, 26, 191
  6. Wade, 2003 May, Int Clin Psychopharmacol, 18, 133
  7. van Willigenburg, 2004, World J Biol Psych, 5, 93
  8. Barilla, 2004, World J Biol Psych, 5, 93
  9. Weiser, 2004 Jun 14, Mov Disord, 19, 205
  10. Brown, 1999, Eur J Psychiatry, 13, 197
  11. Brown, 2000, Eur J Psychiatry, 14, 15
  12. Norinder, 2000 Apr 5, Lakartidningen, 97, 1693
  13. Ravindran, 2005, Geriatrics Aging, 8, 20

Cited by

See all 158

Metadata

Authors
Croom, K. F., Perry, C. M., & Plosker, G. L.
Affiliations
Wolters Kluwer Health (NZ)
Corresponding author
Plosker, Greg L.
Venue
CNS Drugs
Published
2009-05
Volume
23
Issue
5
Pages
427-452
ISSN
1172-7047 (ISSN-L)
OpenAlex
W2000591684
Cited by
158
References
129
Citations by year
2026: 7 · 2025: 8 · 2024: 9 · 2023: 8 · 2022: 10 · 2021: 10 · 2020: 9 · 2019: 7 · 2018: 8 · 2017: 13 · 2016: 5 · 2015: 8 · 2014: 6 · 2013: 10 · 2012: 17
FWCI
9.58
Type
journal article
Language
en
Open access
closed
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
mirtazapine, noradrenergic and specific serotonergic antidepressants, major depressive disorder, antidepressant efficacy, pharmacokinetics, pharmacodynamics, drug interactions, adverse effects, sleep improvement, anxiety disorders, post-traumatic stress disorder, obsessive-compulsive disorder, schizophrenia, elderly patients, REM sleep, enantiomers, CYP3A4, CYP2D6
MeSH terms
Mirtazapine, Antidepressive Agents, Tricyclic, Anxiety Disorders, Major Depressive Disorder, Humans, Mianserin, Psychiatric Status Rating Scales, Databases, Bibliographic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mirtazapine: A Review of its Use in Major Depression and Other Psychiatric Disorders. https://app.cochat.ai/papers/10.2165/00023210-200923050-00006
The paper
Croom, K. F., Perry, C. M., & Plosker, G. L. (2009). Mirtazapine: A Review of its Use in Major Depression and Other Psychiatric Disorders. CNS Drugs. https://doi.org/10.2165/00023210-200923050-00006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.